Becton, Dickinson and Company (BMV:BDX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 699.38B -25.5% |
| Revenue (ttm) | 400.70B +15.5% |
| Net Income | 20.53B -24.0% |
| EPS | 71.85 -22.8% |
| Shares Out | n/a |
| PE Ratio | 34.06 |
| Forward PE | 11.10 |
| Dividend | 77.11 (3.09%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 20 |
| Average Volume | 1,850 |
| Open | 2,526.20 |
| Previous Close | n/a |
| Day's Range | 2,526.20 - 2,526.20 |
| 52-Week Range | 2,498.49 - 3,535.21 |
| Beta | n/a |
| RSI | 25.85 |
| Earnings Date | May 7, 2026 |
About BMV:BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, va... [Read more]
Financial Performance
In fiscal year 2025, BMV:BDX's revenue was $21.84 billion, an increase of 8.24% compared to the previous year's $20.18 billion. Earnings were $1.68 billion, a decrease of -1.58%.
Financial numbers in USD Financial StatementsNews
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures. FRANKLIN LAKES, N.J.
These 5 Stocks Have 50 Years of Dividend Growth—Here's How to Find More
With a new presidential administration set to take office on Jan. 20, 2025, some investors may be uncertain about how new policies and personnel will affect the stock market and interest rates. Will t...
Peter Menziuso Named EVP and President, BD Interventional
FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named execu...
AI, Robotics Key to Transforming Health Care: BD CEO
Tom Polen, CEO of medical technology company BD, says that in the next decade AI and robotics will transform health care in ways that will make today's system seem archaic. Polen sits down with Bloomb...
Becton, Dickinson and Company Transcript: Bank of America Global Healthcare Conference 2026
Leadership is focused on transparency, disciplined capital allocation, and operational rigor. Portfolio reshaping has prioritized high-growth med tech segments, with 30% of the business growing double digits. Margin expansion is driven by productivity, cost management, and favorable mix, while headwinds from Alaris, vaccines, and China are being actively managed.
Becton Dickinson price target raised to $204 from $202 at Barclays
Barclays raised the firm’s price target on Becton Dickinson (BDX) to $204 from $202 and keeps an Overweight rating on the shares post the fiscal Q2 report. Becton delivered solid…
Becton, Dickinson and Company Q2 Earnings Call Highlights
Becton, Dickinson and Company NYSE: BDX reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook...
Becton Dickinson names Vitor Roque CFO
Becton Dickinson (BDX) announced that Vitor Roque has been named executive vice president and CFO, effective May 7. Roque has served as interim CFO since December 2025. With more than…
Becton, Dickinson and Company Earnings Call Transcript: Q2 2026
Q2 revenue rose 2.6% to $4.7B, with strong growth in key platforms and adjusted EPS of $2.90. Full-year adjusted EPS guidance was raised to $12.52–$12.72, reflecting broad-based execution and improved outlook. Share repurchases and innovation remain capital priorities.
Becton, Dickinson and Company Slides: Q2 2026
Becton, Dickinson and Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 7, 2026.
Becton, Dickinson and Company Earnings release: Q2 2026
Becton, Dickinson and Company released its Q2 2026 earnings on May 7, 2026, summarizing the period's financial results.
Becton, Dickinson and Company Quarterly report: Q2 2026
Becton, Dickinson and Company has published its Q2 2026 quarterly earnings report on May 7, 2026.
Becton Dickinson raises annual profit forecast on strength in drug delivery devices
Becton Dickinson raised its annual profit forecast on Thursday, riding strong demand for its drug-delivery devices and surgical equipment, and appointed Vitor Roque as its chief financial officer.
BD Appoints Vitor Roque Chief Financial Officer
FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive...
BD Reports Second Quarter Fiscal 2026 Financial Results
Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repur...
Notable companies reporting before tomorrow’s open
Notable companies reporting before tomorrow’s open, with earnings consensus, include McDonald’s (MCD), consensus $2.74… Howmet Aerospace (HWM), consensus $1.11… Datadog (DDOG), consensus 51c… Zoetis (...
Becton Dickinson, Wellstar partner for medication management
Becton Dickinson (BDX) announced a strategic partnership with Wellstar Health System to enhance the safety and quality of medication delivery for patients across its hospitals and care facilities. ann...
BD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI
By integrating the BD Pyxis™ Pro and BD Alaris™ platforms, Wellstar Health System is giving clinicians clearer insight, greater accuracy and simple automation, so they can focus on delivering safer, m...
Becton Dickinson resumed with an Outperform at Evercore ISI
Evercore ISI resumed coverage of Becton Dickinson (BDX) with an Outperform rating and $180 price target Becton Dickinson is in a transition year with the biosciences and diagnostics separation and…
Becton Dickinson price target lowered to $163 from $189 at TD Cowen
TD Cowen analyst Joshua Jennings lowered the firm’s price target on Becton Dickinson (BDX) to $163 from $189 and keeps a Hold rating on the shares. The firm believes Nthe…
BD Achieves Excellence in Employee Well‑Being, Earning Top Industry Recognition
Business Group on Health, Cigna Healthcare, and the American Heart Association highlight BD's comprehensive and innovative approach to advancing employee health and well being FRANKLIN LAKES, N.J., Ap...
BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
With the launch of CentroVena One™, BD brings a first ‑ of ‑ its ‑ kind insertion system to market that simplifies central line placement for clinicians and enhances care in acute settings FRANKLIN LA...
BD Board Declares Dividend
FRANKLIN LAKES, N.J., April 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has decla...
BD to Present at Bank of America Securities Health Care Conference
FRANKLIN LAKES, N.J., April 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of Am...
Becton Dickinson price target lowered to $159 from $170 at Piper Sandler
Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson (BDX) to $159 from $170 and keeps a Neutral rating on the shares. The firm is tweaking…